2017 |
Aguirre, P; Garcia-Beltran, O; Tapia, V; Munoz, Y; Cassels, B K; Nunez, M Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe2+/Cu2+ Chelator in Cell and Animal Models of Parkinson's Disease Artículo de revista Acs Chemical Neuroscience, 8 (1), pp. 178-185, 2017, ISSN: 1948-7193. Resumen | Enlaces | BibTeX | Etiquetas: activity, antioxidant antioxidant, basal brain chelator, complex content, coumarin-based coumarins, disease, ganglia, i, inhibitory-activity, iron iron-copper lipid-peroxidation, model, mouse neurodegeneration neurodegeneration, neuroprotection, niptp oxidative parkinsons stress, with @article{RN346, title = {Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe2+/Cu2+ Chelator in Cell and Animal Models of Parkinson's Disease}, author = { P. Aguirre and O. Garcia-Beltran and V. Tapia and Y. Munoz and B.K. Cassels and M. Nunez}, url = {/brokenurl#<Go to ISI>://WOS:000392459400021}, doi = {10.1021/acschemneuro.6b00309}, issn = {1948-7193}, year = {2017}, date = {2017-01-01}, journal = {Acs Chemical Neuroscience}, volume = {8}, number = {1}, pages = {178-185}, abstract = {Disturbed iron homeostasis, often coupled to mitochondrial dysfunction, plays an important role in the progression of common neurodegenerative diseases such as Parkinson's disease (PD). Recent studies have underlined the relevance of iron chelation therapy for the treatment of these diseases. Here we describe the synthesis, chemical, and biological characterization of the multifunctional chelator 7,8-dihydroxy-4-((methylamino)methyl)-2H-chromen-2-one (DHC12). Metal selectivity of DHC12 was Cu2+ similar to Fe2+ > Zn2+ > Fe3+. No binding capacity was detected for Hg2+, co(2+), ca(2+), Mnz+, Mg2+, Ni2+, Pb2+ or Cd2+. DHC12 accessed cells colocalizing with Mitotracker Orange, an indication of mitochondrial targeting. In addition, DHC12 chelated mitochondrial and cytoplasmic labile iron. Upon mitochondrial complex I inhibition, DHC12 protected plasma membrane and mitochondria against lipid peroxidation, as detected by the reduced formation of 4-hydroxynonenal adducts and oxidation of C11-BODIPY581/891. DHC12 also blocked the decrease in mitochondrial membrane potential, detected by tetrarnethylrhodamine distribution. DHC12 inhibited MAO-A and MAO-B activity. Oral administration of DHC12 to mice (0.25 mg/kg body weight) protected substantia nigra pars compacta (SNpc) neurons against MPTP-induced death. Taken together, our results support the concept that DHC12 is a mitochondrial-targeted neuroprotective iron-copper chelator and MAO-B inhibitor with potent antioxidant and mitochondria protective activities. Oral administration of low doses of DHC12 is a promising therapeutic strategy for the treatment of diseases with a mitochondrial iron accumulation component, such as PD.}, keywords = {activity, antioxidant antioxidant, basal brain chelator, complex content, coumarin-based coumarins, disease, ganglia, i, inhibitory-activity, iron iron-copper lipid-peroxidation, model, mouse neurodegeneration neurodegeneration, neuroprotection, niptp oxidative parkinsons stress, with}, pubstate = {published}, tppubtype = {article} } Disturbed iron homeostasis, often coupled to mitochondrial dysfunction, plays an important role in the progression of common neurodegenerative diseases such as Parkinson's disease (PD). Recent studies have underlined the relevance of iron chelation therapy for the treatment of these diseases. Here we describe the synthesis, chemical, and biological characterization of the multifunctional chelator 7,8-dihydroxy-4-((methylamino)methyl)-2H-chromen-2-one (DHC12). Metal selectivity of DHC12 was Cu2+ similar to Fe2+ > Zn2+ > Fe3+. No binding capacity was detected for Hg2+, co(2+), ca(2+), Mnz+, Mg2+, Ni2+, Pb2+ or Cd2+. DHC12 accessed cells colocalizing with Mitotracker Orange, an indication of mitochondrial targeting. In addition, DHC12 chelated mitochondrial and cytoplasmic labile iron. Upon mitochondrial complex I inhibition, DHC12 protected plasma membrane and mitochondria against lipid peroxidation, as detected by the reduced formation of 4-hydroxynonenal adducts and oxidation of C11-BODIPY581/891. DHC12 also blocked the decrease in mitochondrial membrane potential, detected by tetrarnethylrhodamine distribution. DHC12 inhibited MAO-A and MAO-B activity. Oral administration of DHC12 to mice (0.25 mg/kg body weight) protected substantia nigra pars compacta (SNpc) neurons against MPTP-induced death. Taken together, our results support the concept that DHC12 is a mitochondrial-targeted neuroprotective iron-copper chelator and MAO-B inhibitor with potent antioxidant and mitochondria protective activities. Oral administration of low doses of DHC12 is a promising therapeutic strategy for the treatment of diseases with a mitochondrial iron accumulation component, such as PD. |
2017 |
Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe2+/Cu2+ Chelator in Cell and Animal Models of Parkinson's Disease Artículo de revista Acs Chemical Neuroscience, 8 (1), pp. 178-185, 2017, ISSN: 1948-7193. |